NCT03996486View on ClinicalTrials.gov

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 28, 2019

Primary Completion Date

May 29, 2020

Study Completion Date

July 31, 2020

Conditions
Hemophilia
Interventions
DRUG

BAY1093884

Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03996486 - Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia | Biotech Hunter | Biotech Hunter